ArticleEuropean journal of preventive cardiology2026
Development and validation of the CARE-DM model to predict the cardiovascular risk in older persons with type 2 diabetes.
Article in European journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsNo cardiovascular risk prediction model dedicated to individuals aged ≥70 years with diabetes is currently recommended by the European Society of Cardiology. We aimed to develop a new model, CArdiovascular Risk Estimation-Diabetes Mellitus (CARE-DM), to predict the risk of cardiovascular disease (CVD) in older adults with type 2 diabetes. METHODS AND
resultsWe developed a model to predict the risk of incident CVD in participants aged ≥65 years with diabetes using data from four population-based prospective cohorts, accounting for the competing risk of non-cardiovascular death. Pre-specified predictors were age, gender, smoking status, alcohol consumption, body mass index, total and HDL cholesterol, use of antihypertensive, cholesterol-lowering and glucose-lowering medication, diabetes duration, and glycated haemoglobin. We assessed model performance using measures of calibration and discrimination. We used a 10-fold cross-validation and a bootstrapping approach to correct estimates for optimism and conducted an internal-external cross-validation. A total of 6943 participants (median age 72 years, 56% women) with diabetes were included in the model development. Over a median follow-up of 6.3 (interquartile range 3.7, 7.2) years, 1204 (17.3%) participants experienced a CVD event. Internal validation with optimism correction showed adequate model performance with a C-index of 0.65 (95% confidence interval 0.63-0.67), an observed-to-expected ratio of 1.01 (0.95-1.08), and a calibration slope of 1.13 (0.95-1.31) at 5 years.
conclusionThe new CARE-DM model allows prediction of the incident CVD risk in older adults with type 2 diabetes. Independent external validation should be conducted to confirm the model's performance before implementation in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.